Leads Biolabs Maintains Stable Share Base in March 2026; Confirms Public-Float Compliance

Bulletin Express
04/01

Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital for the month ended 31 March 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing Limited.

Authorised/registered share capital remained unchanged at RMB 198.89 million, comprising: • 153.28 million H-shares listed in Hong Kong with a nominal value of RMB 1 each. • 45.61 million unlisted domestic shares, also at RMB 1 par value.

Issued share capital mirrored the authorised structure and likewise showed no change during the month: • 153.28 million H-shares in issue and nil treasury shares. • 45.61 million unlisted shares in issue.

The company confirmed that as at 31 March 2026 the applicable minimum public-float threshold—25 % of the total issued H-shares—was satisfied.

No share options, warrants, convertible securities, or other agreements that could lead to equity dilution were outstanding or executed during the period, and no treasury-share transactions occurred.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10